Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents
Copyright policy )Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents
AbstractWe prospectively investigated the changes of liver stiffness (LS) and the occurrence of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) eradication using direct antiviral agents (DAA) over three years. LS measurement using transient elastography and serum fibrosis surrogate markers before treatment and at 48, 96, 144 weeks after starting direct-acting antivirals (DAA) according to the protocol were evaluated. Patients were also compared with historical cohort treated with pegylated interferon (peg-IFN). Sustained viral response (SVR) was observed in 95.8%. LS value in the patients achieving SVR significantly decreased over time (19.4 ± 12.9 kPa [baseline], 13.9 ± 9.1 kPa [48 weeks], 11.7 ± 8.2 kPa [96 weeks], 10.09 ± 6.23 [144 weeks], all p < 0.001). With matched analysis, the decrease in LS value was significantly larger in DAA group than peg-IFN group at both 48 weeks (29% vs. 9%) and 96 weeks (39% vs. 17%). The incidence of HCC was not significantly different between DAA and peg-IFN groups (5.5% vs. 5.4%) at 144 weeks. HCV eradication with DAA can lead to improvement of liver stiffness over time. The regression of fibrosis was greater in the group with DAA than peg-IFN.Clinical trials registration: ClinicalTrials.gov (NCT02865369).
- Yonsei University Korea (Republic of)
- Soonchunhyang University Hospital Bucheon Korea (Republic of)
- Korea University Ansan Hospital Korea (Republic of)
- Hanyang University Seoul Hospital Korea (Republic of)
- Inha University Hospital Korea (Republic of)
Liver Cirrhosis, Male, Time Factors, Pyrrolidines, Sustained Virologic Response, Administration, Oral, Antiviral Agents / adverse effects, Chronic / drug therapy*, Carbamates / administration & dosage, Prospective Studies, Hepatocellular / virology, Liver Neoplasms / diagnosis, Incidence, Q, Liver Neoplasms, R, Imidazoles, Liver Neoplasms / epidemiology, Middle Aged, Hepatitis C, Hepatocellular / diagnosis, Treatment Outcome, Administration, Combination, Imidazoles / administration & dosage, Medicine, Elasticity Imaging Techniques, Liver Cirrhosis / epidemiology, Drug Therapy, Combination, Female, Chronic / diagnosis, Liver Cirrhosis / diagnostic imaging, Oral, Liver Cirrhosis / drug therapy*, Carcinoma, Hepatocellular, Seoul, Science, 610, Antiviral Agents, Liver Cirrhosis / virology, Article, Drug Therapy, Ribavirin / administration & dosage, Humans, Sulfonamides / administration & dosage, Retrospective Studies, Aged, Antiviral Agents / administration & dosage*, Carcinoma, Liver Neoplasms / prevention & control*, Chronic / virology, Pyrrolidines / administration & dosage, Hepatitis C, Chronic, Isoquinolines, Isoquinolines / administration & dosage, Hepatocellular / epidemiology, Interferons / administration & dosage, Liver Neoplasms / virology, Chronic / epidemiology, Carbamates, Interferons, Hepatocellular / prevention & control*
Liver Cirrhosis, Male, Time Factors, Pyrrolidines, Sustained Virologic Response, Administration, Oral, Antiviral Agents / adverse effects, Chronic / drug therapy*, Carbamates / administration & dosage, Prospective Studies, Hepatocellular / virology, Liver Neoplasms / diagnosis, Incidence, Q, Liver Neoplasms, R, Imidazoles, Liver Neoplasms / epidemiology, Middle Aged, Hepatitis C, Hepatocellular / diagnosis, Treatment Outcome, Administration, Combination, Imidazoles / administration & dosage, Medicine, Elasticity Imaging Techniques, Liver Cirrhosis / epidemiology, Drug Therapy, Combination, Female, Chronic / diagnosis, Liver Cirrhosis / diagnostic imaging, Oral, Liver Cirrhosis / drug therapy*, Carcinoma, Hepatocellular, Seoul, Science, 610, Antiviral Agents, Liver Cirrhosis / virology, Article, Drug Therapy, Ribavirin / administration & dosage, Humans, Sulfonamides / administration & dosage, Retrospective Studies, Aged, Antiviral Agents / administration & dosage*, Carcinoma, Liver Neoplasms / prevention & control*, Chronic / virology, Pyrrolidines / administration & dosage, Hepatitis C, Chronic, Isoquinolines, Isoquinolines / administration & dosage, Hepatocellular / epidemiology, Interferons / administration & dosage, Liver Neoplasms / virology, Chronic / epidemiology, Carbamates, Interferons, Hepatocellular / prevention & control*
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).25 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!